Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
NEW YORK (Reuters Health) – Outcomes of cryoablation of small renal masses are similar whether the procedure is performed surgically or percutaneously, according the results of a meta-analysis…
NEW YORK (Reuters Health) – The likelihood that a core needle biopsy diagnosis of ductal carcinoma in situ (DCIS) will be upstaged to invasive breast cancer on final…
NEW YORK (Reuters Health) – In terms of overall survival, carboplatin plus the oral fluoropyrimidine derivative S-1 is as effective as carboplatin plus paclitaxel in chemotherapy-naive patients with…
NEW YORK (Reuters Health) – Patients with papillary thyroid cancer who undergo lobectomy do as well as those who undergo total thyroidectomy, while external beam radiation is associated…
NEW YORK (Reuters Health) – The risk of second primary neoplasms (SPNs) of the central nervous system in survivors of childhood cancer increases greatly with the dose of…
NEW YORK (Reuters Health) – The off-label use of recombinant factor VIIa for hemostasis in patients without hemophilia confers only modest benefits but may increase the risk of…
NEW YORK (Reuters Health) – Compared with zoledronic acid, the monoclonal antibody denosumab is more effective in delaying skeletal-related events in women with breast cancer that has metastasized…
NEW YORK (Reuters Health) – The tyrosine kinase inhibitors gefitinib or erlotinib may slow the development of central nervous system metastases in patients with advanced non-small cell lung…
NEW YORK (Reuters Health) – Women with breast cancer treated with anthracycline-taxane based regimens are more likely to become amenorrheic than women treated with just anthracyclines or conventional…
NEW YORK (Reuters Health) – After first-line treatment with bevacizumab plus interferon-alpha2a, subsequent therapy with tyrosine kinase inhibitors (TKIs) improves survival in patients with metastatic renal cell carcinoma,…
